AstraZeneca's (AZN,AZN.L,ZEG.DE,AZN.ST) Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer—previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC)—as detected by a US Food and Drug Administration (FDA)-authorised test.
Concurrently with this approval, the US Food and Drug Administration also authorised a companion diagnostic test designed to detect PTEN deficiency in tumours of patients with prostate adenocarcinoma. This ensures that eligible individuals can be accurately identified for treatment with the Truqap combination.
A regulatory application for the Truqap regimen in this setting is currently under review in the European Union. The submission is supported by data from the CAPItello-281 Phase III trial, which evaluated the efficacy and safety of the combination in patients with PTEN-deficient metastatic prostate cancer.
AZN closed Friday's regular trading at $178.75 down $3.53 or 1.94%. But in the after-hours trading the stock gained $2.05 or 1.15%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.